Drugs /

avitinib

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.

Clinical Trials

View Clinical Trials for avitinib

Avitinib has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating avitinib, 1 is phase 2 (1 open) and 1 is phase 3 (0 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for avitinib clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in avitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Avitinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Avitinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating avitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ac 0010, ac-0010, ac0010, abivertinib, abivertinib maleate, avitinib maleate
Drug Target(s) [2]:
BTK, EGFR
NCIT ID [1]:
C118671

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.